E2814 (etanlanetug) is an anti-tau monoclonal antibody developed by Eisai Co., Ltd. that specifically targets the microtubule-binding region (MTBR) of tau protein. This represents a novel approach in tau-targeted therapy, as most previous anti-tau antibodies targeted the N-terminus of tau, which showed limited efficacy in clinical trials. E2814 is the first MTBR-targeting antibody to advance to late-stage clinical testing.
¶ Tau Biology and Pathological Relevance
Tau protein is a microtubule-associated protein that stabilizes axonal microtubules in neurons. In Alzheimer's disease and other tauopathies, tau becomes abnormally hyperphosphorylated, aggregates into neurofibrillary tangles (NFTs), and spreads throughout the brain in a characteristic pattern.
The tau protein has several key regions:
flowchart TD
A["Tau Protein"] --> B["N-Terminal Region"]
A --> C["Proline-Rich Region"]
A --> D["Microtubule-Binding Region"]
A --> C-Terminal Region
D --> D1["3R Tau"]
D --> D2["4R Tau"]
B --> B1["Anti-tau antibodies targeting N-terminus - Limited efficacy"]
D --> D2["Anti-tau antibodies targeting MTBR - E2814 Novel approach"]
E2814 binds to tau aggregates in the brain and specifically targets the MTBR region, particularly:
- p-tau396/404: Phosphorylated tau at positions 396 and 404
- p-tau217: Another key phosphorylation site in the MTBR
- MTBR residues 244-368: Core region involved in tau filament formation
By targeting this region, E2814 aims to:
- Block tau aggregation: Prevent new tau filament formation by binding to the aggregation-prone region
- Promote clearance: Facilitate removal of pathological tau species via the immune system
- Prevent propagation: Block templated spread of tau pathology between neurons
- Target filament core: Directly bind the structural core of tau aggregates
| Target Region |
Antibody |
Company |
Result |
| N-terminus |
Gosuranemab |
Roche |
Failed Phase 2 |
| N-terminus |
Tilavonemab |
AbbVie |
Failed Phase 2 |
| N-terminus |
Zagotenemab |
Eli Lilly |
Failed Phase 2 |
| N-terminus |
Semorinemab |
Roche |
Failed Phase 2 |
| MTBR |
E2814 |
Eisai |
Phase 2/3 |
| MTBR |
Bepranemab |
UCB |
Phase 2 |
The failures of N-terminal targeting antibodies demonstrated that not all tau epitopes are suitable for therapeutic targeting. The MTBR, being the structural core of tau filaments, represents a more direct target.
The Phase 1 study (NCT04622375) was a first-in-human trial evaluating the safety, tolerability, pharmacokinetics, and target engagement of E2814.
Key Findings:
- Safety profile: E2814 was well-tolerated at all doses tested
- Dose-dependent engagement: Clear dose-dependent relationship between drug exposure and CSF tau changes
- CSF tau reduction: Significant reduction in CSF tau levels at higher doses
- Brain target engagement: Evidence of tau engagement in the brain via PET imaging
Dosing:
- Multiple ascending dose cohorts
- Intravenous administration
- Doses ranging from low to high mg/kg
Additional Phase 1 studies in healthy volunteers and patients established:
- Pharmacokinetics: Suitable half-life for IV dosing
- Pharmacodynamics: Biomarker changes consistent with target engagement
- Dose selection: Rationale for Phase 2 dose selection
E2814 is being evaluated in the DIAN-TU (Dominantly Inherited Alzheimer Network Trials Unit) study, which focuses on individuals with autosomal dominant Alzheimer's disease.
| Trial |
Phase |
Status |
NCT Number |
Population |
| E2814-001 |
Phase 1 |
Completed |
NCT04622375 |
Healthy volunteers, early AD |
| DIAN-TU-001 |
Phase 2/3 |
Active |
NCT05256190 |
Autosomal dominant AD |
DIAN-TU Background:
- Genetic form of AD caused by deterministic mutations (APP, PSEN1, PSEN2)
- Predictable age of onset allows pre-symptomatic intervention
- Multiple arms testing different disease-modifying therapies
- Gold standard for testing prevention approaches in AD
E2814 DIAN-TU Design:
- Randomized, double-blind, placebo-controlled
- Pre-symptomatic and early-symptomatic carriers
- Primary endpoint: Clinical and biomarker outcomes
- Long-term follow-up for safety and efficacy
E2814 development includes advanced tau imaging:
- Tau PET ligands: Use of flortaucipir and next-generation tau tracers
- Regional analysis: Assessment of tau burden in specific brain regions
- Treatment effects: Evaluation of tau PET changes over time
- Correlation with clinical outcomes: Linking imaging to cognitive measures
¶ Target Engagement and Biomarkers
Key CSF biomarkers being monitored:
| Biomarker |
What It Measures |
Expected Change |
| Total tau |
Overall tau pathology |
Reduction |
| Phosphorylated tau (p-tau181, p-tau217) |
Pathological tau |
Reduction |
| Neurofilament light (NfL) |
Neurodegeneration |
Potential reduction |
- Amyloid PET: Baseline amyloid burden for patient selection
- Tau PET: Regional tau load and treatment effects
- FDG-PET: Glucose metabolism as neurodegeneration marker
Primary and secondary clinical endpoints:
- Cognitive tests: CDR-SB, ADAS-Cog13, MMSE
- Functional measures: ADCS-ADL
- Patient-reported outcomes: Quality of life measures
Previous anti-tau antibodies that targeted the N-terminus of tau all failed in Phase 2 trials:
- Gosuranemab (NCT03352557): Failed to meet primary endpoint
- Tilavonemab (NCT03518073): No significant benefit over placebo
- Zagotenemab (NCT03289143): Did not demonstrate efficacy
Several hypotheses explain the failures:
- Non-pathogenic fragments: N-terminal tau fragments may not be pathologically relevant
- Insufficient brain penetration: Antibodies may not reach intracellular tau
- Wrong mechanism: Clearing extracellular tau may not address intracellular pathology
- Epitope accessibility: N-terminal epitopes may not be accessible to antibodies
The MTBR targeting approach is more promising because:
- Core of pathology: MTBR is the structural core of tau filaments
- Aggregation domain: Contains the region that drives aggregation
- Conformational changes: Pathological conformations expose this region
- Preclinical validation: Strong preclinical data supporting this approach
¶ Antibody Characteristics
- Isotype: Humanized IgG1
- Mechanism: Monoclonal antibody
- Affinity: High-affinity binding to pathological tau
- Selectivity: Preference for aggregated over monomeric tau
- Administration: Intravenous infusion
- Dosing interval: Monthly or less frequent dosing
- Half-life: Extended half-life enabling less frequent dosing
- Distribution: CNS penetration sufficient for target engagement
The Phase 1 studies demonstrated:
- Generally well-tolerated: No significant safety signals
- No dose-limiting toxicity: Maximum tolerated dose not reached
- Infusion reactions: Manageable, generally mild
- No ARIA: Unlike anti-amyloid antibodies, no amyloid-related imaging abnormalities observed
Long-term safety studies include:
- Regular MRI monitoring
- CSF safety biomarkers
- Adverse event tracking
- Immunogenicity assessment
¶ Antibody Approaches
| Drug |
Target |
Epitope |
Company |
Phase |
Notes |
| E2814 |
MTBR |
p-tau396/404 |
Eisai |
Phase 2/3 |
DIAN-TU |
| Bepranemab |
MTBR |
p-tau217 |
UCB |
Phase 2 |
Different epitope |
| Semorinemab |
N-terminus |
Not applicable |
Roche |
Failed |
First generation |
| Gosuranemab |
N-terminus |
Not applicable |
Roche |
Failed |
First generation |
| Approach |
Example |
Company |
Stage |
| ASO |
BIIB080 |
Biogen/Ionis |
Phase 2 |
| ASO |
NIO752 |
Roche |
Phase 1 |
| Small molecule |
LY3372689 |
Eli Lilly |
Phase 2 |
| Vaccine |
ACI-35 |
AC Immune |
Phase 1/2 |
E2814 could be evaluated in other tauopathies:
- Progressive Supranuclear Palsy (PSP): 4R-tauopathy
- Corticobasal Degeneration (CBD): 4R-tauopathy
- Frontotemporal Lobar Degeneration (FTLD): Various tau subtypes
Future development may include:
- Combination with anti-amyloid: Sequential or concurrent therapy
- Combination with other mechanisms: Multiple disease-modifying targets
- Earlier intervention: Pre-symptomatic treatment in at-risk populations
E2814 represents a potentially paradigm-shifting approach to tau-targeted therapy:
- Novel mechanism: First MTBR-targeting antibody in late-stage trials
- Genetic validation: Based on understanding of tau biology
- Differentiated approach: Learning from previous antibody failures
- DIAN-TU platform: Rigorous testing in genetically defined population
The success of E2814 would validate MTBR targeting as a viable strategy and potentially bring the first effective anti-tau therapy to patients.